Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Exercise  COVID-19 treatment studies for Exercise  C19 studies: Exercise  Exercise   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Exercise for COVID-19: real-time meta analysis of 33 studies
Covid Analysis, May 22, 2022, DRAFT
https://c19early.com/exmeta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Hamer 28% 0.72 [0.61-0.87] hosp. n/a n/a Improvement, RR [CI] Treatment Control Hamer 34% 0.66 [0.55-0.79] hosp. n/a n/a Brawner 74% 0.26 [0.11-0.58] hosp. n/a n/a Zhang 26% 0.74 [0.48-1.14] death n/a n/a Zhang 18% 0.82 [0.69-0.96] cases n/a n/a Tavakol 69% 0.31 [0.10-1.02] severe case 3/64 19/124 Yates 45% 0.55 [0.38-0.79] death 72/163,912 62/30,119 Yates 47% 0.53 [0.43-0.66] severe case 291/163,912 180/30,119 Holt 17% 0.83 [0.63-1.09] cases n/a n/a Cho 53% 0.47 [0.26-0.87] death case control Cho 10% 0.90 [0.86-0.95] cases case control Sallis 59% 0.41 [0.22-0.76] death 11/3,118 170/6,984 Sallis 42% 0.58 [0.40-0.85] ICU 32/3,118 195/6,984 Sallis 53% 0.47 [0.38-0.58] hosp. 99/3,118 732/6,984 Christensen 63% 0.37 [0.16-0.85] death 543 (n) 529 (n) Christensen 23% 0.77 [0.52-1.15] cases 55/543 77/529 Latorre-Román 76% 0.24 [0.05-1.04] hosp. n/a n/a Latorre-Román 87% 0.13 [0.01-1.17] hosp. n/a n/a Marcus 42% 0.58 [0.48-0.71] symp. case 240/10,627 134/3,708 Yuan 91% 0.09 [0.01-1.65] death 0/61 6/103 Yuan 70% 0.30 [0.09-0.92] severe case 3/61 26/103 Brandenburg -6% 1.06 [0.23-4.79] hosp. 102 (n) 39 (n) Brandenburg 78% 0.22 [0.05-1.02] hosp. 177 (n) 34 (n) Brandenburg 64% 0.36 [0.13-0.98] hosp. 97 (n) 34 (n) Brandenburg 35% 0.65 [0.28-1.48] severe case 102 (n) 39 (n) Brandenburg 24% 0.76 [0.28-2.04] severe case 52 (n) 34 (n) Bielik 30% 0.70 [0.40-1.21] mod. case 775 (n) 365 (n) Bielik -9% 1.09 [0.69-1.73] cases 775 (n) 365 (n) Lee 74% 0.26 [0.07-0.99] death 2/11,072 32/41,293 Lee 58% 0.42 [0.19-0.91] severe case 39/11,072 273/41,293 Lee 16% 0.84 [0.73-0.98] cases 291/11,072 1,293/41,293 Maltagliati 52% 0.48 [0.25-0.87] hosp. n/a n/a Baynouna AlKetbi 98% 0.01 [0.00-0.44] death n/a n/a Ahmadi 30% 0.70 [0.54-0.89] death 160/232,613 112/95,221 Nguyen 20% 0.80 [0.72-0.88] symp. case 904/2,836 483/1,111 Lin 47% 0.53 [0.12-2.33] cases n/a n/a de Souza 73% 0.27 [0.07-1.06] ventilation 3/611 6/327 de Souza 34% 0.66 [0.43-0.99] hosp. 49/611 42/327 Mohsin 19% 0.81 [0.66-0.99] severe case 86/258 224/544 Mohsin -1% 1.01 [0.88-1.15] severe case 290/698 224/544 Ekblom-Bak 48% 0.52 [0.30-0.92] severe case n/a n/a Lengelé 74% 0.26 [0.07-0.80] cases 23/229 4/12 Saadeh 9% 0.91 [0.56-1.43] symp. case 362 (n) 225 (n) Saadeh 4% 0.96 [0.62-1.43] symp. case 362 (n) 225 (n) Hamrouni 29% 0.71 [0.55-0.92] death 138/106,006 109/47,827 Huang 47% 0.53 [0.23-1.22] severe case 7/74 16/90 Huang 8% 0.92 [0.30-2.85] severe case 3/23 20/141 Huang 66% 0.34 [0.17-0.70] cases n/a n/a Steenkamp 42% 0.58 [0.50-0.68] death 29,469 (n) 13,366 (n) Steenkamp 45% 0.55 [0.47-0.64] ventilation 29,469 (n) 13,366 (n) Steenkamp 41% 0.59 [0.52-0.66] ICU 29,469 (n) 13,366 (n) Gilley -42% 1.42 [0.60-3.35] cases 172/1,917 5/79 Beydoun 43% 0.57 [0.32-1.01] cases 1,710 (n) 448 (n) Beydoun 62% 0.38 [0.18-0.78] cases 672 (n) 448 (n) Salgado-Aranda 83% 0.17 [0.05-0.56] death 4/223 41/297 Paul 38% 0.62 [0.30-1.20] no recov. n/a n/a Paul 4% 0.96 [0.53-1.63] no recov. n/a n/a Kontopoulou 66% 0.34 [0.24-0.47] recov. time 42 (n) 24 (n) Kontopoulou 67% 0.33 [0.24-0.46] no recov. 42 (n) 24 (n) exercise COVID-19 outcomes c19early.com/ex May 2022 Favors exercise Favors inactivity
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit